NEW ACR2020 Draft Guidelines for the Pharmacologic Treatment of RA All the guidelines in 2 tables! 1. MTX 1st, oral > SC 2. Minimize GC! 3. TTT TTT TTT 4. Biologic/tsDMARD > Triple Tx 5. Taper MTX 1st Close to my practice; suspect will be controversial! #ACR20 #ACRambassador https://t.co/iFSlq1H65V

Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020

Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated? #ACR20 @RheumNow

Just as a reminder of how we felt back then. https://t.co/onIMqa5DAp Also note, the hypogammaglob gap has widened a little (then 25 v 21, now 36 v 26). Now we have the extended follow-up data, where no additional benefit was noted, do we still feel that excited? #ACR20 @RheumNow

• https://twitter.com/drdavidliew/status/1193573759749365760?s=20

Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo

RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC

Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow

GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?

When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing

Rheum Now shares Day 3 highlights from #ACR20. https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh

• https://bit.ly/2IhSKj0

Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/iFaMRNB5D3

Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy

These kind of studies must be done, but this result is to nobody’s surprise! #PedsRheum Let’s keep working together to move the bar towards recognition that #sJIA and #AOSD are a single condition that can affect people of all ages! https://t.co/qzbgeKPlqw

• https://twitter.com/bella_mehta/status/1325831474004824064

Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk

• https://twitter.com/janetbirdope/status/1325489723922591745